• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Protagonist Therapeutics Inc.

    5/13/25 12:10:05 PM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PTGX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    PROTAGONIST THERAPEUTICS INC

    (Name of Issuer)


    COMMON STOCK

    (Title of Class of Securities)


    74366E102

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    74366E102


    1Names of Reporting Persons

    STATE STREET CORPORATION
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,535,466.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,706,619.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,706,619.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.4 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    PROTAGONIST THERAPEUTICS INC
    (b)Address of issuer's principal executive offices:

    7707 GATEWAY BLVD SUITE 140 , NEWARK, CALIFORNIA, 94560
    Item 2. 
    (a)Name of person filing:

    STATE STREET CORPORATION;
    (b)Address or principal business office or, if none, residence:

    ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES
    (c)Citizenship:

    MA
    (d)Title of class of securities:

    COMMON STOCK
    (e)CUSIP No.:

    74366E102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    2706619.00
    (b)Percent of class:

    4.4  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    2,535,466

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    2,706,619

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    NOT APPLICABLE
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    SSGA FUNDS MANAGEMENT, INC. (IA);STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA);STATE STREET GLOBAL ADVISORS LIMITED (IA);STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA);STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED (IA);STATE STREET GLOBAL ADVISORS, LTD. (IA);
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    NOT APPLICABLE
    Item 9.Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.


    NOT APPLICABLE

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    STATE STREET CORPORATION
     
    Signature:ELIZABETH SCHAEFER
    Name/Title:SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
    Date:05/09/2025
    Get the next $PTGX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PTGX

    DatePrice TargetRatingAnalyst
    12/6/2024$47.00Neutral
    Goldman
    12/6/2024$62.00Outperform
    BMO Capital Markets
    11/5/2024$58.00Outperform
    Wedbush
    9/24/2024$65.00Buy
    TD Cowen
    9/9/2024$60.00Buy
    Truist
    10/30/2023$32.00Overweight
    CapitalOne
    5/25/2023$30.00 → $40.00Buy
    Jefferies
    8/25/2022$21.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $PTGX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

      − Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo − All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes − Rusfertide was generally well tolerated; no new safety findings were observed in the study Protagonist Therapeutics, Inc. ("Protagonist") ((PTGX) and Takeda ((TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all fou

      3/3/25 6:45:00 AM ET
      $PTGX
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Protagonist Therapeutics Reports Granting of Inducement Awards

      NEWARK, CALIFORNIA / ACCESSWIRE / January 6, 2025 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today reported that on January 2, 2025, it issued inducement awards to Newman Yeilding, M.D., upon his appointment to the role of Executive Vice President, Chief Scientific Officer, in accordance with the terms of his employment offer letter. Dr. Yeilding served in a consultant role as the Company's Chief Scientific Advisor from August 1, 2024 through January 1, 2025. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.Dr. Yeilding received options to purchase 38,520 sh

      1/6/25 4:05:00 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025

      NEWARK, CA / ACCESSWIRE / December 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a company overview at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 12-16, 2025 in San Francisco, CA. The Company will also participate in one-on-one meetings.43rd Annual J.P. Morgan Healthcare Conference - January 12-16, 2025Format: Company PresentationDay/Time: Tuesday, January 14 at 8:15AM PTWebcast: https://jpmorgan.metameetings.net/events/healthcare25/sessions/58274-protagonist-therapeutics-inc/webcast?gpu_only=true&kiosk=trueIf you are interested in meeting

      12/19/24 4:05:00 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Selick Harold E exercised 10,725 shares at a strike of $1.16, increasing direct ownership by 32% to 43,851 units (SEC Form 4)

      4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)

      4/30/25 4:45:59 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Ali Asif sold $80,776 worth of shares (1,756 units at $46.00), decreasing direct ownership by 3% to 61,065 units (SEC Form 4)

      4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)

      4/23/25 4:30:15 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Waddill William D. sold $217,000 worth of shares (4,000 units at $54.25), decreasing direct ownership by 23% to 13,130 units (SEC Form 4)

      4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)

      3/19/25 4:01:12 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Protagonist Therapeutics with a new price target

      Goldman initiated coverage of Protagonist Therapeutics with a rating of Neutral and set a new price target of $47.00

      12/6/24 8:23:16 AM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BMO Capital Markets initiated coverage on Protagonist Therapeutics with a new price target

      BMO Capital Markets initiated coverage of Protagonist Therapeutics with a rating of Outperform and set a new price target of $62.00

      12/6/24 8:11:17 AM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Protagonist Therapeutics with a new price target

      Wedbush initiated coverage of Protagonist Therapeutics with a rating of Outperform and set a new price target of $58.00

      11/5/24 6:25:30 AM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTGX
    Leadership Updates

    Live Leadership Updates

    See more

    $PTGX
    SEC Filings

    See more

    $PTGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor

      Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I spaceNEWARK, CA / ACCESSWIRE / July 31, 2024 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced the appointment of Newman Yeilding, M.D. to the role of Chief Scientific Advisor, effective August 1, 2024. Dr. Yeilding is an accomplished physician-scientist with deep knowledge and expertise in inflammatory, rheumatology, autoimmune and immunologic diseases. As Chief Science Advisor, he will provide discovery,

      7/31/24 9:15:00 AM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Protagonist Therapeutics Set to Join S&P SmallCap 600

      NEW YORK, June 27, 2024 /PRNewswire/ -- Protagonist Therapeutics Inc. (NASD: PTGX) will replace Encore Wire Corp. (NASD: WIRE) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 3. S&P Europe 350 constituent Prysmian SpA (MTAA: PRY) is acquiring Encore Wire in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector July 3, 2024 S&P SmallCap 600 Addition Protagonist Therapeutics PTGX Health Care S&P SmallCap 600 Deletion Encore Wire WIRE Industrials For more information a

      6/27/24 5:44:00 PM ET
      $PTGX
      $SPGI
      $WIRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance
    • Turnstone Biologics Appoints William Waddill to its Board of Directors

      SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,

      4/16/24 9:00:00 AM ET
      $ANNX
      $ARWR
      $PTGX
      $TSBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • SEC Form SCHEDULE 13G filed by Protagonist Therapeutics Inc.

      SCHEDULE 13G - Protagonist Therapeutics, Inc (0001377121) (Subject)

      5/13/25 12:10:05 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Protagonist Therapeutics Inc.

      10-Q - Protagonist Therapeutics, Inc (0001377121) (Filer)

      5/6/25 5:04:48 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Protagonist Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Protagonist Therapeutics, Inc (0001377121) (Filer)

      5/6/25 4:27:37 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Protagonist Therapeutics Inc.

      SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)

      11/14/24 4:27:37 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Protagonist Therapeutics Inc.

      SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)

      11/12/24 4:51:49 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Protagonist Therapeutics Inc.

      SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)

      11/4/24 1:22:14 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTGX
    Financials

    Live finance-specific insights

    See more
    • Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

      − Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo − All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes − Rusfertide was generally well tolerated; no new safety findings were observed in the study Protagonist Therapeutics, Inc. ("Protagonist") ((PTGX) and Takeda ((TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all fou

      3/3/25 6:45:00 AM ET
      $PTGX
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate

      Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF)IND enabling studies underway, with Phase I initiation expected in Q425Webcast and conference call to be held today at 4:30 pm ET NEWARK, CA / ACCESSWIRE / November 21, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced the selection of PN-881, a potential best-in-class oral peptide interleukin-17 (IL-17) antagonist, as a development candidate for the treatment of immune-mediated skin diseases."We are extremely pleased to nominate development candidate PN-881, a promising potential best-in-class oral peptide IL

      11/21/24 4:05:00 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate

      Webcast and conference call to be held be on Thursday, November 21st at 4:30 pm ET, dial in information belowNEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral peptide IL-17 antagonist development candidate and to share in vitro and pre-clinical proof-of-concept study results.Conference Call and Webcast DetailsThe dial-in numbers for Protagonist's investor update on Thursday, November 21st at 4:30 pm ET are:US-based Investors: 1-877-407-0752International Investors: 1-201-389-0912Conference Call ID: 13750274The webcast link for the event can

      11/19/24 7:30:00 AM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care